brochure
Transcription
brochure
Our commitment Our values As a leader in orthopaedic innovation, Corin has pioneered a number of landmark orthopaedic developments since it was founded in 1985. We are very proud that we have been able to improve the quality of life of hundreds of thousands of patients across the world through the introduction of these ground breaking products, and believe this heritage distinguishes Corin within the global orthopaedic market. Quality focus Our talented and dedicated teams continue to share a common commitment – delivering quality orthopaedic products and services to patients, surgeons and healthcare providers, which exceed their expectations and positively impact their lives, through Responsible Innovation. Ensuring quality is the primary core value across the business. Technical excellence Building and developing talented teams who are experts in their field. Creative enthusiasm Empowering individuals to seek innovative solutions and continuous improvements. Responsive support Responding quickly and resourcefully to our internal and external customers. Positive impact Making a real difference and influencing positive change for patients, surgeons, healthcare providers and our company. This is the cornerstone of everything we do. Responsible Innovation Our experience Corin is a world leader in the development, production and distribution of a wide range of cutting edge, reconstructive orthopaedic devices. We are committed to finding new and innovative solutions to positively impact the lives of patients around the globe. With an increasingly active and demanding patient population, the need to provide stateof-the-art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin’s hip continuum of care and knee portfolio are designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance. Applying our in-house knowledge and experience, coupled with the know-how of eminent surgeons, Corin’s innovative product offering today includes a wide range of cuttingedge brands. Alongside Trinity™ advanced bearing acetabular cup, MiniHip™ conservative stem, TriFit TS™ cementless tapered stem, MetaFix™ cementless stem and TaperFit™ cemented stem, Corin’s pioneering hip portfolio also incorporates ECiMa™ next generation vitamin E highly cross-linked polyethylene and Biomimetic Cementless Technology. 4 | Unity Knee™ is the most recent addition to our knee portfolio, which also encompasses Uniglide™ unicompartmental knee and Rotaglide+™ total knee. Unity brings a new dimension to patients and surgeons, helping to address long-standing issues of patient satisfaction and wear. Within our wider product portfolio and further extending our range of advanced treatment options, Zenith™ total ankle replacement and LARS™ soft tissue internal fixation also play an important role in bringing quality of life to patients. The growing proportion of people undergoing joint replacement from the ageing population, combined with increased expectations for an active lifestyle, mean that demand for new, innovative and durable products remains high. With a reputation for breaking new ground, Corin’s commitment to restoring quality of life remains strong, through continued investment in new technologies and new product development. Our focus With advances in healthcare across the globe and higher expectations for a sustained quality of life well into old age, the world is seeing an ageing, more active population. This in turn is driving growth in the international orthopaedic market as the demand for procedures increases. In order to support patients and healthcare professionals around the world, our strategy is focused on the following areas: Broaden Extending our hip and knee portfolio Innovate Developing new implant solutions Strengthen Increasing our global sales presence Responsible Innovation | 5 Our geography Corin has direct operations in eight of the world’s major orthopaedic markets, with distribution arrangements in over 30 other countries. Corin subsidiaries Australia Austria Germany Italy Japan South Africa United Kingdom United States Global partners Argentina Barbados Belgium Bolivia Brazil Canada Colombia Costa Rica Croatia Cyprus Czech Republic Dominican Republic Ecuador Egypt Ghana Greece India 6 | Israel Italy Korea Lebanon Malaysia Mexico Netherlands Pakistan Poland Portugal Russia Spain Sweden Thailand Turkey United Arab Emirates Venezuela Responsible Innovation | 7 Our history Since its foundation in 1985, Corin has grown from a small UK orthopaedic business to a global orthopaedic solutions provider with operations in 40 countries worldwide. Throughout this rapid growth phase Corin has established a strong presence across key orthopaedic segments, providing innovative and unique solutions to longstanding patient complications and challenges. In 2008, a new senior management team instigated a five year strategic plan initiating major investment into new product development. Since this time Corin has seen approvals for its new continuum of care portfolio in most leading global markets, including the US, Europe, South America and Australia, along with world leading technology launches such as ECiMa™ advanced bearing technology, allowing better treatment options for active patients. 8 | In 2013 Corin was acquired by the private equity team, 2IL Orthopaedics, opening up new opportunities for expansion and accelerated growth. ■■ Corin is founded in Cirencester, UK, deriving its name from the town’s name in Roman Britain, Corinium. 1985 ■■ Corin USA established. 1992 ■■ Corin McMinn hip resurfacing is launched. 1989 ■■ Corin Japan established. 1997 1989 1997 2002 Rotaglide™ Cormet™ Uniglide™ AMC™ knee system is launched – first true meniscal bearing knee system on the market. hip resurfacing is launched. 1995 TaperFit™ cemented hip system is launched. New knee products are introduced through Alphanorm acquisition. ■■ ■■ Corin floats on the London Stock Exchange. Corin acquires Alphanorm (later to become Corin Germany) to gain presence in the German and Austrian markets. 2002 ■■ Corin achieves sales in excess of £20m. 2003 New senior management team embark on renewed five year strategic plan with major investment in new product development. Corin expands UK headquarters to new site. ■■ ■■ Corin Australia established. ■■ 2004 ■■ Corin achieves sales in excess of £40m. Collaboration with a leading research institute to develop ECiMa™ next-generation vitamin E technology. Global supply agreement signed with MAKO Surgical Corp, to provide total hip solutions for the Rio™ interactive robotic system. 2009 2010 ■■ ■■ 2008 FDA approval for Cormet™ in the USA. ■■ 2007 ■■ Corin acquired by 2IL Orthopaedics, opening new opportunities for growth. 2013 ■■ Corin South Africa and Corin Italy established. 2014 2008 2009 2011 2012 2014 MetaFix™ Zenith™ MiniHip™ ECiMa™ Unity Knee™ Revival™ cementless hip and total ankle system are launched. bone conserving hip system is launched. next generation vitamin E technology is launched. 2010 Trinity™ advanced bearing acetabular cup system is launched. revision hip platform introduced to the Corin hip continuum of care. the world’s first fifth generation knee system launched. 2013 blade stem based on extensive global CT patient data is launched. Responsible Innovation | 9 Our hip portfolio Today’s patients expect, and deserve, to have access to the very latest treatment options. With a global population that is living longer and becoming more active, the need to ensure conservative and effective treatment pathways has never been more important. Corin’s hip continuum of care is designed to provide each patient with the optimal patient matched solution, using some of the most advanced bearing technologies in the world. Trinity™ Advanced Bearing Acetabular System MiniHip™ Bone Conserving Hip Replacement Cementless Tapered Hip Replacement MetaFix™ Cementless Total Hip Replacement TaperFit™ Cemented Total Hip Replacement Revival™ Modular Revision Hip System 10 | Responsible Innovation | 11 Our knee portfolio Corin has long established its credentials in providing unique world class knee solutions. Learning from the experience of over 40 years of total knee development, Unity Knee™ is the latest evolution in total knee arthroplasty – unifying key design technologies with advanced knee kinematics, soft tissue preservation concepts and modern surgical principles. Unity joins our portfolio alongside Uniglide™, one of the most comprehensive mobile and fixed bearing unicompartmental knee offerings, Rotaglide+™, the world’s first truly mobile knee system, and AMC II™ total knee platform. Uniglide™ Unicompartmental Knee Replacement Unity Knee™ Total Knee System Rotaglide+™ Total Knee System AMC II™ Total Knee System 12 | Our wider portfolio Zenith™ total ankle replacement provides a high performance alternative to ankle fusion. Together with an innovative implant design concept, advanced material technology and state of the art instrumentation, Zenith™ is designed to restore confidence in total ankle surgery. LARS™ is one of the most advanced nonbiological soft tissue treatment options, providing a conservative alternative to the need to harvest existing soft tissues. Zenith™ Total Ankle Replacement LARS™ Soft Tissue Internal Fixation Solomax™ Pulsed Lavage System Responsible Innovation | 13 Our technology Corin has developed a worldwide network of research associations with leading universities, research institutes and industrial partners, ensuring that we stay at the forefront of innovation. State of the art test methodologies are used to develop and verify new technologies to demonstrate the safety and efficacy of all our prostheses. Advanced computer simulation technologies model and predict the lifecycle of prostheses, whilst kinematic analysis and mechanical simulations are used to replicate patients’ behaviour, ensuring that product performance is optimised over the life of the implant. Research into new materials allows us to offer world first technologies for the next decade through developing products based on the very best in implant technology, designed to enhance longevity and performance. The focus of research concentrates on providing patient benefits to improve quality of life in a society of increasingly active arthritic patients – minimising wear, addressing aseptic loosening and reducing stress shielding that can cause bone loss around implants and increased revision rates. Corin has a first class track record of gaining access to external grant funding (Technology Strategy Board, NIHR i4i and EU funding) and 14 | running multidisciplinary research projects with a clear end goal – to develop products for improved patient function and benefit. Research outputs are disseminated at international conferences and via publications in peer-reviewed journals in collaboration with our global research partners and key opinion leaders. ECiMa™ In a unique collaboration, Corin has worked with a leading research institute on the development and commercialisation of a next generation vitamin E polyethylene. The result, ECiMa™, is a cold-irradiated, mechanically-annealed, vitamin E-blended ultra high molecular weight polyethylene (UHMWPE). The most advanced polyethylene of its kind, ECiMa™ has been developed to minimise wear, improve oxidation resistance in today’s increasingly younger and more active patients, and to offer mechanical properties superior to other conventional highly cross-linked polyethylenes due to its unique process. Global collaboration Corin is engaged in world class collaborations with global innovation leaders in the pursuit of the ‘forgotten implant’ – an implant offering such performance that the patient forgets its presence. Next generation porous implants with enhanced fixation and bone adaptive structures that minimise stress shielding are being specifically developed for the increasingly younger and more active demographic. Such implants have optimised micro-textured surfaces to improve initial stability and secure rapid osseointegration. The ‘forgotten implant’ will offer increased functionality and longevity, and as research continues will represent the next major advancement in implant technology. Responsible Innovation | 15 16 | Our operation An example of British manufacturing success, all production takes place on-site at our UK headquarters. Our facilities have consistently been updated over the years to encompass the very latest manufacturing technologies and modern production principles, ensuring all Corin products meet the very highest standards in quality engineering. The combination of modern manufacturing methodologies alongside continued investment in high tech computer-controlled machinery ensures the highest level of operational efficiency. This enables us to produce quality products, ensuring the best patient outcomes for our global operating partners. Corin operates in a highly regulated environment with frequent and thorough external quality audits to ensure our continuing compliance with relevant statutory and industry standards. All products are designed to be safe and reliable and comply with, or exceed, all legal and regulatory requirements. Coupled with this quality and technology is a highly skilled and motivated workforce. Our teams combine experienced individuals who have been in medical manufacturing for many years, with the ongoing development of the best local talent through an effective and well-established apprenticeship programme, developed in conjunction with a local university. We have a strong environmental, health and safety awareness across all areas of our business, anticipating future requirements so that the health and safety of customers and patients is continually enhanced. In an ever-competitive market, the culture within Corin encourages people at all levels to engage in an environment of continuous improvement, positively impacting on the growth and development of Corin. Quality is a core value deeply embedded within Corin’s culture across all aspects of the organisation and every product is subject to the highest level of quality assurance. Today, computer aided technology is central to all aspects of our business, from the creation of the initial concept ideas through to the manufacture and measurement of all components using computer-controlled coordinate measuring machines (CMMs) and high-end vision systems. Responsible Innovation 17 Our support Corin Academy was established to provide a wide range of surgeon training initiatives to meet the needs of the changing global orthopaedic community. Through a range of meeting and education formats, our vision is to provide a forum to debate and discuss current concepts and best practice in orthopaedic surgery, and to help build long-term clinical success for today’s patient population. We deliver this through the following initiatives: The eExpert Surgeon eLearning The Visit Centres of Excellence The Experience Live surgery The Masterclass Expert guidance The Science Surgeon-led congress The Lab Cadaveric workshops The Forum Sharing best practice 18 | Surgeon to surgeon visits The ‘Experience’ meeting Utilising the most highly-skilled practitioners to train surgeons on each procedure ensures that best practice is passed on, enabling excellent clinical performance and promoting long-term patient wellbeing as well as outstanding clinical results for Corin manufactured products. Surgeon to surgeon hospital visits offer highly effective one-on-one training opportunities allowing experts to discuss products which are at the foreground of modern orthopaedic practice. These exchanges facilitate opportunities for knowledge transfer in a live theatre environment. Scientific congresses Modern orthopaedic medicine depends on a lively interaction between experts in this ever-changing field. In order to promote such discussion, Corin works diligently with a wide faculty of experts who are able to work with us to put together the most interesting and topical agendas and debates, whilst seeking to drive understanding and illuminate those areas requiring clarity. Through this close interaction with experts, Corin has been able to stay at the cutting edge of orthopaedic practice, to better understand the needs of surgeons and their patients. Each year, the Corin Academy meeting calendar includes the successful ‘Experience’ series. Through recognising the importance of a wide range of inputs and utilising these, we are able to make rapid progress with delegates and help them to greatly improve their understanding of products and procedures in a well-controlled environment. By using an innovative mixture of live video-link surgery, didactic sessions and dry-bone workshops, as well as interactive sessions such as ‘difficult cases’ and ‘what would you do?’, delegates feel that they are able to get the best out of meetings and the valuable time away from their practices. Responsible Innovation | 19 20 | Our service JointResponse™ provides a wide range of innovative reconstructive orthopaedic solutions on a short-term loan basis, working with client hospitals to help them meet their commitments to patients. Corin’s highly trained and professional JointResponse customer support team works in partnership with client hospitals to understand requirements, delivering a personal level of service to meet the exact needs of all our individual customers. a wealth of experience, the dedicated inhouse JointResponse team understands the importance of peace of mind. Whenever an order is placed with one of our friendly and helpful members, you can be assured of a fast, efficient and reliable response. Implants spanning a range of sizes and associated instrumentation are dispatched to the hospital for the duration of surgery and then returned back to Corin. Loan kits are sent out on a guaranteed next morning delivery or they can also be fast-tracked for more urgent requirements. Instrumentation is maintained to the highest standard and supplied in high quality, custombuilt flight cases. Our comprehensive storage system and excellent cleaning facilities ensure that all orders are serviced promptly and accurately. All loan kits are supplied fullyfunctional and decontaminated. We know how important it is that the right implants, together with the right instrumentation, are delivered at exactly the right time. With Responsible Innovation | 21 Our clinical responsibility As an organisation, Corin places a great deal of importance on collaboration with key clinical institutions to deliver strong medical research programmes that support the safe and effective use of Corin implants. Being at the cutting edge of new product development and also with well-established products in our portfolio, Corin has the dual responsibility of dealing with new product introductions as well as the changing face of the global regulatory systems relating to in-market devices. Taking our responsibility for patient wellbeing seriously means investing significantly in short, medium and long-term studies of up to 15 years’ duration. As a company we support registries both locally and globally as well as single and multi-centre, international data collections, in order to monitor the safe and effective use of our devices worldwide. Over recent years we have implemented a dramatic increase in the level of clinical research activity carried out in relation to Corin’s devices. This has been driven by regulatory imperatives and the requirement to support the launch of a series of new hip products through global multi-centre initiatives. As we drive forward, we will continue to develop innovative products in a responsible manner. 22 | Our dedication to clinical data collection is strongly aligned to our enthusiasm for surgeon training, for it can only be by the combination of these two key elements that we will be able to produce long-term clinical efficacy and patient satisfaction. We will continue to invest significantly in robust clinical research in partnership with leading global clinical centres to document the safe and effective use of Corin’s implants – both for surgeons and their patients. Responsible Innovation | 23 24 | Our corporate responsibility Corin is committed to carrying out its operations in a socially and environmentally responsible way. In all aspects of our operations and dealings with customers, business partners, employees, shareholders and the local community, we recognise the importance of corporate responsibility both to our stakeholders and to the long-term success of our business. Our responsibilities to our customers are of paramount importance as we continue to develop and expand our range of products. We provide education and training support for healthcare professionals and maintain a significant investment in research and development. Our products are designed to be safe and reliable, complying with or exceeding all legal and regulatory requirements. Environmentally we recognise the need to protect and preserve the world’s resources and accept our obligations as an organisation to identify and, as far as practicable, to reduce, re-use and recycle any aspect of our activities, products and services that could potentially have an adverse environmental impact. We are committed to comply with all applicable environmental legislation and actively maintain an environmental management system which meets the requirements of ISO 14001. Corin has a formal code of conduct providing guidelines for employees regarding business behaviour, interactions with healthcare professionals, conflicts of interest and the use of intellectual property, information and company resources. We offer employees the encouragement to learn and progress, fairly recognising and rewarding performance. Our recruitment and promotion policies are based solely on qualifications and abilities and we do not tolerate discrimination on any grounds. All operations are conducted in accordance with generally accepted principles and rules of good governance and we aim to provide sustained, profitable growth to our shareholders, valuing their views and recognising their interest in the Group’s strategy and performance. We provide regular information on our activities, structure, financial situation and performance. Corin considers that making a contribution to the communities in which we are based is an important commitment and we support employees who undertake voluntary or community work. We contribute to a number of charitable causes each year, focusing on the provision and promotion of health and welfare services both within the local community and further afield in some of the world’s less developed countries. Responsible Innovation 25 Our future Through sustained investment in our core values, Corin continues to bring benefits to hundreds of thousands of people, delivering on our commitment to provide treatment options that exceed the expectations and positively impact the lives of patients, surgeons and healthcare providers around the world. Responsible Innovation is the cornerstone of everything we do and drives our vision and dedication to become one of the most respected orthopaedic medical device companies in the world. 26 | The Corinium Centre Cirencester, GL7 1YJ United Kingdom t: +44 (0)1285 659 866 f: +44 (0)1285 658 960 e: [email protected] www.coringroup.com This document has been printed in the UK on Novatech Matt paper which is sourced from FSC® Chain of Custody responsibly managed forests. The paper is produced at a mill which holds certifications for ISO 9001 Quality Management System, ISO 14001 Environmental Management Standard and the Carbon Trust Standard. The pulp is bleached using Elemental Chlorine Free processes. If you have finished reading this report and no longer wish to retain it, please pass it on to other interested readers; return it to Corin or dispose of it in your recycled paper waste. Thank you. Responsible Innovation ©2015 Corin P No. I1187 Rev3 02/2015 ECR 13699 Responsible Innovation
Similar documents
to PDF
from Rensselaer Polytechnic Institute. Paul, his wife Marie and their two children currently have relocated to Tampa, FL, the home of Corin USA. In a recent conversation with Russ Mably, COO Corin ...
More informationto PDF
Corin is pleased to announce United States 510(k) clearance of the Optimized Positioning System (OPS™), the first FDA-cleared technology to help surgeons achieve functional, patient specific compon...
More information